News for Axsome Therapeutics Stock (AXSM)

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile Corp • 06/10/22

AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

PRNewsWire • 06/08/22

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile Corp • 06/08/22

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

GlobeNewsWire • 06/06/22

6 Biotech Stocks to Buy Now Ahead of These June Catalysts

InvestorPlace • 06/03/22

AXSM SHAREHOLDER ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

Newsfile Corp • 06/03/22

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile Corp • 06/03/22

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

GlobeNewsWire • 06/02/22

Axsome Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2022 to Discuss Your Rights - AXSM

Newsfile Corp • 06/02/22

Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders

Business Wire • 06/01/22

Why Is Axsome (AXSM) Down 30.3% Since Last Earnings Report?

Zacks Investment Research • 06/01/22

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm

Newsfile Corp • 06/01/22

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

PRNewsWire • 05/31/22

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

GlobeNewsWire • 05/31/22

AXSM LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Axsome Therapeutics, Inc.

Newsfile Corp • 05/31/22

Shareholder Alert: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

Newsfile Corp • 05/28/22

INVESTOR DEADLINE: Investors in Axsome Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSM

Newsfile Corp • 05/27/22

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

Business Wire • 05/26/22

Axsome Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Axsome Therapeutics,

PRNewsWire • 05/26/22

AXSM INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

PRNewsWire • 05/24/22

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)

Business Wire • 05/24/22

INVESTOR ALERT: Investors in Axsome Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSM

Newsfile Corp • 05/24/22

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM

Business Wire • 05/23/22

ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

Newsfile Corp • 05/22/22

INVESTOR DEADLINE: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AXSM

Business Wire • 05/21/22